TM Capital. Success. Realized. | Immucor Goodwill Valuation Analysis

Immucor, Inc. (NASDAQ: BLUD) is the market leader in diagnostic products for blood transfusions, with a market value of over $1 billion
Pursuant to the adoption of FAS 142, Immucor is required to test its goodwill balances, which total $27 million, for impairment
Immucor retained TM Capital to prepare a valuation analysis of each of its global divisions with goodwill balances
TM Capital provided Immucor with its opinion that Immucor’s goodwill balances are not currently subject to impairment

goodwill impairment valuation analysis

TM Capital provided Immucor, Inc. (NASDAQ) with an analysis of goodwill balances for potential impairment pursuant to FAS 142

For more information, contact our healthcare team at:

”

Immucor Goodwill Valuation Analysis